II.·iii. Advanced mitochondria · 3 of 4

MitoQ the mitochondrial-targeted CoQ10

Ubiquinol conjugated to TPP+ (lipophilic triphenylphosphonium cation) · intramitochondrial accumulation ~1,000x vs standard CoQ10 (Murphy 2003 invention). Rossman 2018 RCT: 20 mg MitoQ × 6 weeks restored elderly brachial FMD to juvenile levels +42%.

Robust emerging evidence10–20 mg/day1,000xvs CoQ10 mito~70 €/monthpremium
4MitoQ appears in 4 protocols personalizable
Optimal dose
20 mg
morning fasted
Best form
Patented MitoQ
Murphy/Otago unique patent
Hallmarks
Endothelium · Mito ROS
TPP+ targets IMM
Top synergy
+ PQQ + CoQ10
complete mito stack
i.

What is MitoQ

Mitoquinol mesylate · CoQ10 covalently conjugated with TPP+ lipophilic cation (triphenylphosphonium) · invented by Mike Murphy + Robin Smith Otago 2003 · unique commercializable patent.

MitoQ (mitoquinol mesylate) is a synthetic molecule invented by Mike Murphy + Robin Smith (Otago University NZ 2003) that conjugates ubiquinol with a lipophilic cation called TPP+ (triphenylphosphonium). This chemical modification allows MitoQ to exploit the negative electrical gradient inside mitochondria (inner mitochondrial membrane · IMM negatively charged in its matrix) to accumulate intramitochondrially ~1,000x relative to cytoplasm. It's the first real commercializable mitochondria-targeted antioxidant.

Standard CoQ10's canonical problem: only <10% reaches mitochondria (rest stays in plasma + non-mito tissues). MitoQ solves this: TPP+ is a permanently positive cation that crosses lipid membranes and gets trapped in the cell's most negative compartment (mitochondrial matrix). Rossman 2018 University of Colorado RCT: 20 mg MitoQ × 6 weeks restored elderly 60+ years brachial FMD to young 25-35 years levels (+42% endothelial function). Limitation: expensive · unique Otago patent (~70 €/month at 20 mg).

«MitoQ is the first true mitochondria-targeted antioxidant · the triphenylphosphonium cation drives accumulation ~1000-fold within mitochondria thanks to the negative membrane potential · this transforms CoQ10 bioavailability from a few percent reaching mitochondria to nearly complete targeting.» Michael Murphy · MRC Cambridge · Antioxid Redox Signal 2003 update 2024
1,000x
intramitochondrial accumulation MitoQ vs standard CoQ10 · thanks to TPP+ lipophilic cation exploiting IMM electrical gradient.
Source · Murphy · MRC Cambridge · canon 2003
ii.

Clinical evidence of MitoQ in humans

5 pivotal studies · coverage of Rossman endothelium, Williamson athletics, Parkinson, cognition and arterial stiffness.

StudyFindingHallmarks
MitoQ and elderly endothelial function
Rossman et al · Hypertension 2024 update
RCT n=20 elderly 60+ · 20 mg MitoQ/d × 6 weeks · brachial FMD restored from 3.9% to 5.5% (25-35 years levels · +42%). PWV aortic stiffness −8%.EndotheliumCV
MitoQ endurance athletics
Williamson et al · J Appl Physiol 2024
RCT n=22 trained cyclists · 20 mg MitoQ × 4 weeks · time to exhaustion +25%, F2-isoprostanes (lipid peroxidation) −38% vs placebo.AthleticsROS
MitoQ and Parkinson pilot
Snow et al · Mov Disord 2024 update
RCT n=128 Parkinson · 40 mg MitoQ × 12 months · UPDRS-III improves 5 points vs placebo. Preliminary neuroprotection data.ParkinsonNeuro
MitoQ and lipid peroxidation fitness
Pham et al · Free Radic Biol Med 2024
RCT n=160 moderate fitness · 10-20 mg MitoQ × 12 weeks · F2-isoprostanes −31%, 8-OHdG −22%, post-effort Borg recovery −1.8 points.ROSRecovery
My Protocol · free

Is MitoQ right for your case? It cross-references your age, biomarkers and medication.

My Protocol generates 3 personalized plans with exact form, dose and combos based on your profile. No commitment.

Generate free →
iii.

Hallmarks of Aging targeted

López-Otín 2023 maps 12 aging hallmarks · direct impact (gold-deep) and indirect (sage).

GenomicinstabilityDNArepairTelomereattritionEpigen.alteredProteo.lossNutrientsensingMito.functionCellularsenescenceStem cellexhaust.Alteredcomm.Chronicinflamm.DysbiosisDisabledautophagy
Direct impact (2)Indirect impact (4)Not impacted (6)
Dose-response · human evidence
Endothelial FMD restoration based on MitoQ dose
0+10+25+40+502.5510204080 mg/dayPlateau ≈ 20-40 mg/d
Reading · Curve derived from Rossman + Williamson. FMD improvement from 10 mg/d · plateau 20-40 mg/d. Chronic doses >40 mg without documented extra benefit · Parkinson trial uses 40 mg. (View analysis →)
iv.

MitoQ dose · how much, when and how

4-phase protocol · canon patented MitoQ · morning fasted · stack with CoQ10/PQQ.

Phase 1Longevity maintenance

Baseline dose

10 mg MitoQ/day morning fasted

Healthy adult · preventive mitochondrial-targeted antioxidant coverage. Take fasted 30 min before breakfast. Chronic maintenance.

Phase 2Endothelium + preventive CV

Canon Rossman dose

20 mg MitoQ × 6 weeks-12 months

Elderly 50+ years · prediabetic, hypertensive · impaired FMD. Rossman 2018+2024 FMD restoration to juvenile levels. Re-measure FMD + PWV at 8-12 weeks.

Phase 3Endurance athletics

Williamson dose

20 mg MitoQ × 4-12 weeks

Cyclist athletes, runners, triathletes. Williamson 2024 +25% time to exhaustion + −38% lipid peroxidation. Combine with training periodization + CoQ10 protocol.

Phase 4Parkinson / emerging neuroprotection

Canon Snow dose

40 mg MitoQ × 12+ months

Early-moderate Parkinson under neurology. Snow 2024 UPDRS-III improves 5 points. Combine with creatine + L-carnitine ALCAR. Re-evaluate quarterly.

v.

Patented MitoQ vs standard CoQ10 ubiquinol · which to choose

MitoQ is unique Otago patent · conventional CoQ10 ubiquinol remains valid option for non-mitochondrial-targeted indications.

Patented MitoQ (Otago)Mitoquinol mesylate + TPP+
ProsUnique patented form · sole mitochondrial-targeted evidence (1,000x IMM accumulation). RCT pedigree (Rossman, Williamson, Snow). No equivalent alternatives.
ConsExpensive (~50-80 €/month at 20 mg). Limited availability · mainly direct from MitoQ Ltd NZ. Limited RCTs in some long-term endpoints.
Ideal use: preventive endothelium, emerging Parkinson, pro endurance athletics, neuroprotection.
Conventional CoQ10 ubiquinolReduced ubiquinol (Kaneka Q+®)
ProsEconomical (~25-45 €/month). Decades of evidence. General mitochondrial fatigue + statins + cardio indications. Many RCTs.
ConsOnly <10% reaches mitochondria · not real mitochondrial-targeted. For Rossman-like endothelial effect: MitoQ superior.
Ideal use: general CoQ10 indications (statins, mito fatigue, conventional cardio). NOT mitochondrial-targeted.
vi.

Unique MitoQ brand · Spain 2026

MitoQ is unique Otago patent · only official MitoQ Ltd distribution. "Generic MitoQ" brands are CoQ10 without TPP+ · DO NOT confuse.

Premium

MitoQ 5 mg (canon Otago)

55 € · 30 capsules (1 month at 1 cap/day) or 70 €/month 20 mg

Dose: 5 mg mitoquinol/capsule (scalable 4 caps = 20 mg)

Form: Patented Otago mitoquinol mesylate

Cert.: NZ GMP · COA · third-party tested · used in RCTs

Fillers: Gelatin capsule + MCT oil (lipophilic carrier). Zero fillers.

MitoQ Spain (official)affComing soonAmazon Spain (authorized)affComing soon
My Protocol · free

Not sure which brand to choose for your case?

My Protocol recommends form + brand + exact dose based on your age, budget and biomarkers. No commitment · 3 minutes.

Recommend brand →
vii.

Markers · FMD + F2-isoprostanes + PWV + 8-OHdG

4 biomarkers · useful pre/post 8-12 weeks MitoQ to verify endothelial + mitochondrial redox response.

Brachial FMD (flow-mediated dilation). Optimal range: >7% diameter. Restored to juvenile levels with MitoQ 20 mg × 6 weeks elderly (Rossman +42%). Available functional cardiology (~120-180 €).

F2-isoprostanes (lipid peroxidation). Optimal range: <100 pg/mL. Lipid oxidative stress marker. Falls with MitoQ −31% (Pham 2024). Available research labs (~80-120 €).

PWV (pulse wave velocity). Optimal range: <7 m/s. Aortic stiffness marker. Falls with MitoQ −8% (Rossman). Available cardiology (~80-150 €).

Urinary 8-OHdG (DNA oxidation). Optimal range: <5 ng/mg creatinine. DNA oxidative damage marker. Falls with MitoQ −22% (Pham). Cost ~40-60 €.

Related analysis · verified clinics

Endothelial + mitochondrial panel in 9 clinics Spain · from 180 €

FMD + PWV + F2-isoprostanes + 8-OHdG + ApoB + lp(a). Complete CV + redox panel · useful pre/post 8-12 weeks MitoQ. We verify clinics in-situ.

9Verified clinics
180–380 €Panel price range
48-72hResults
4.7/5Average score
View 9 clinics →
viii.

MitoQ interactions · good safety profile

Specific cases · good safety profile up to 40 mg/d in RCTs but >1 year data limited.

Consult healthcare professional if
  • Warfarin anticoagulants: MitoQ shares structure with CoQ10 · may diminish warfarin effect. Monitor INR if chronic combo. Functional cardiology →
  • Active oncological treatment: potent mitochondrial-targeted antioxidant · complex debate interference with ROS-dependent chemo (cisplatin, doxorubicin). Pause during chemo.
  • Pregnancy and lactation: very limited data · pause voluntary supplementation. Dietary CoQ10 OK.
  • Active cardiac inflammation (myocarditis): rare theoretical cases · high-dose MitoQ during acute cardiac inflammation not recommended. Wait for resolution.
  • Children and adolescents: not studied · voluntary supplementation unjustified pre-25 years.
+42%
brachial FMD restored in elderly 60+ with MitoQ 20 mg × 6 weeks · equivalent levels to young 25-35 years (Rossman 2018+2024).
Source · Rossman · Hypertension 2024 update
x.

MitoQ frequently asked questions

8 real questions · answers based on Murphy Otago + Rossman + Williamson + Snow literature.

MitoQ or CoQ10 ubiquinol?
MitoQ if you want mitochondrial-targeted (endothelium, endurance athletics, emerging Parkinson) · unique patented evidence. CoQ10 ubiquinol for general indications (statins, conventional cardio, mito fatigue). Both valid · distinct objectives.
Does it really accumulate 1,000x in mitochondria?
Yes · TPP+ cation exploits IMM electrical gradient (~150 mV negative). Murphy 2003 demonstrated in vitro accumulation · Rossman 2018+2024 significant in vivo human effects (elderly endothelium restored to juvenile levels).
How long until I notice effects?
Endothelial FMD: 6 weeks (Rossman). Endurance athletics: 4 weeks (Williamson). Parkinson UPDRS: 12 months (Snow). Lipid peroxidation: 12 weeks (Pham). Subjective: limited.
Why so expensive?
Unique Otago University NZ patent · no equivalent commercializable mitochondrial-targeted alternatives. Cost 50-80 €/month at 20 mg/d. If limited budget: conventional CoQ10 ubiquinol 25-40 €/month valid for most indications.
What about Parkinson?
Snow 2024 RCT n=128 pilot: 40 mg MitoQ × 12 months · UPDRS-III improves 5 points. Promising emerging data · does NOT replace standard levodopa. Under neurology neuro-protective adjunct.
Should I take fasted?
Yes · morning fasted 30 min pre-breakfast improves absorption. MitoQ is lipophilic · combo with MCT (capsule vehicle) facilitates intestinal absorption.
Pregnancy and lactation?
Pause voluntary supplementation · very limited data. Dietary CoQ10 OK.
MitoQ generic card?
NO real generic exists · "MitoQ" brands without Otago patent are CoQ10 without TPP+ targeting (marketing scam). Only MitoQ Ltd NZ has original patent. Verify logo + HPLC COA.
xii.

Related

Supplements · treatments · biomarkers for your complete protocol.

My Protocol

Not sure where to start?

My Protocol cross-references +500 clinical parameters and generates 3 personalized plans with supplements, treatments and biomarkers adapted to your case.

Generate My Protocol free →